Novanta (NOVT) Q1 2026 Earnings Transcript

Novanta reported Q1 revenue growth of 10% reported and 3% organic, with bookings up 37% and adjusted EBITDA up 14% to $57 million, while adjusted EPS rose 9% to $0.81. Management raised full-year revenue guidance to $1.04 billion-$1.055 billion and highlighted strong demand in GenAI infrastructure, robotics, and medical solutions, but gross margin fell 60 bps to 45.6% due to tariffs, freight, and materials inflation. Cash flow was strong at $52 million, company buybacks totaled $18 million, and the balance sheet remained in net cash at $139 million.

Analysis

NOVT is showing the classic shape of an industrial compounder entering an upswing: orders are inflecting faster than revenue, while cash conversion is unusually strong because working capital is still being harvested from prior-period execution. The important second-order read is that the backlog is increasingly tied to GenAI infrastructure, advanced packaging, and precision manufacturing rather than a single end-market, which should make the growth curve less brittle than a pure semicap proxy. That said, this is still a price/cost timing story in the near term, not a clean margin expansion story, because booked revenue limits how quickly tariff pass-through can fully offset the shock.

The margin reset looks temporary, but the timing matters. Because a large portion of the year is already booked, the company is forced to reprice existing backlog rather than simply reprice new orders, which creates a quarter-to-quarter lag that can keep reported gross margin under pressure into Q2 before improving more visibly in Q3/Q4. The real upside catalyst is not just demand strength; it is the combination of manufacturing consolidation, repricing, and mix shift toward higher-Vitality new products, which can expand EBITDA faster than revenue once the cost stack normalizes.

The market may be underestimating how much of NOVT’s semiconductor/AI exposure is actually embedded in niche manufacturing tools and precision subsystems rather than the obvious AI beneficiaries. That makes the stock a softer way to express the AI capex theme, but also means it can rerate quickly if investors realize the 15% AI-linked revenue base is growing off a much smaller installed share than consensus likely models. The contrarian risk is that tariff volatility persists longer than management expects, and because the company already has favorable bookings visibility, any further input-cost spike would hit sentiment before it hits revenue.

Key Decisions for Investors

• Long NOVT into any post-earnings dip over the next 1-3 weeks; target a 6-12 month hold for margin recovery and backlog conversion. Risk/reward improves if the market prices it as a low-quality industrial rather than an AI-enabled compounder.
• Pair trade: long NOVT / short a broader industrial ETF or slower-growth industrial hardware name over 3-6 months. Thesis: NOVT has better organic growth acceleration, stronger cash conversion, and a clearer Q3/Q4 margin inflection.
• If seeking AI-capex exposure with less beta than NVDA, use NOVT as a partial substitute position over the next 2-4 quarters. Upside comes from hidden infrastructure content; downside is lower valuation multiple compression if tariff noise persists.
• For more aggressive expression, buy NOVT call spreads dated 6-9 months out to capture the expected second-half margin step-up. Structure around the Q3 inflection where repricing and site closures should begin to show through.
• Avoid shorting here unless you have a near-term tariff escalation view; the setup has positive backlog visibility and cash flow support, so the bear case likely needs a macro or policy shock rather than a fundamental demand miss.